<![CDATA[Lenvatinib/Pembrolizumab Shows Promise After IO Progression in GYN Cancers]]>

Data ReadoutpositiveLenvatinibPembrolizumabPositive

AI Analysis

Summary

A retrospective series reported a 75% response rate when lenvatinib was added after pembrolizumab progression in patients with dMMR endometrial cancer, suggesting potential clinical benefit for the combination approach.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

75% response rate observed when adding lenvatinib after pembrolizumab progression in dMMR endometrial cancer

Importance:5/10

Sentiment:

0.70

gynecologic cancersendometrial cancerdMMRimmuno-oncologycombination therapyretrospective analysis

Related Companies

$ESALY $MRK

Read the original article

Published by Cancer Network on August 20, 2026 8:00 PM

Read Original